Information Provided By: 
Fly News Breaks for May 23, 2017
ZBH, NUVA, SYK, MDT, ISRG, EW, BSX, BDX, BAX, ABMD, ABT
May 23, 2017 | 08:21 EDT
Morgan Stanley upgraded the Medtech Technology sector to Attractive saying structural fundamentals have improved and recent acceleration will likely continue, driving further multiple expansion.
News For ABT;ABMD;BAX;BDX;BSX;EW;ISRG;MDT;SYK;NUVA;ZBH From the Last 2 Days
ABT
Apr 18, 2024 | 21:44 EDT
ISRG
Apr 18, 2024 | 17:52 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSMetropolitan... To see the rest of the story go to thefly.com. See Story Here
ISRG
Apr 18, 2024 | 17:00 EDT
Sees FY24 gross profit margin 67%-68%. Sees FY24 operating expense up 11%-15%. Sees FY24 capital expenditures 1B-$1.2B. Sees FY24 tax rate 22%-24%. Says five additional procedures will have reimbursement in Japan by June. Says saw particular strength in the U.S. and the U.K. Comments and guidance taken from Q1 earnings conference call.
ISRG
Apr 18, 2024 | 16:08 EDT
ISRG
Apr 18, 2024 | 13:20 EDT
Pre-earnings options volume in Intuitive Surgical is 2.0x normal with calls leading puts 10:9. Implied volatility suggests the market is anticipating a move near 4.9%, or $18.11, after results are released. Median move over the past eight quarters is 5.6%.
ISRG
Apr 18, 2024 | 13:16 EDT
ABT
Apr 18, 2024 | 09:14 EDT
RBC Capital lowered the firm's price target on Abbott to $125 from $128 but keeps an Outperform rating on the shares. The analyst states that despite a strong Q1 with 10.8% underlying revenue and double-digit EPS growth, the stock was down 3%, which reflects sentiment on the broader MedTech space, where high expectations require a beat and raise for stocks to be rewarded. RBC maintains however that it sees upside potential for Abbott "as 2024 drivers take hold".
ABT
Apr 18, 2024 | 09:01 EDT
ABT
Apr 17, 2024 | 16:32 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
BSX
Apr 17, 2024 | 14:32 EDT
ABT
Apr 17, 2024 | 11:59 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
ABT
Apr 17, 2024 | 10:00 EDT
Says pipeline contributing at an "accelerated level." Says more opportunities vs. risks going forward. Targeting about 70 bps in gross margin improvement in FY24. Says FX challenges still remain. Says all business segments "super well aligned" to demographics, health care trends.
ABT
Apr 17, 2024 | 09:41 EDT
Unusual total active option classes on open include: Steel Dynamics (STLD), Gildan Activewear (GIL), Danaher (DHR), Altimeter Growth (GRAB), Childrens Place (PLCE), ASML (ASML), US Bancorp (USB), iShares Barclays 7 to 10 Year Treasury Bond Fund (IEF), AMC Entertainment (AMC), and Abbott (ABT).
ABT
Apr 17, 2024 | 09:16 EDT
ABT
Apr 17, 2024 | 08:56 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. HIGHER - Alcoa (AA)... To see the rest of the story go to thefly.com. See Story Here
ABT
Apr 17, 2024 | 07:36 EDT
ABT
Apr 17, 2024 | 07:34 EDT
Worldwide Medical Devices sales increased 14.2% on a reported basis and 14.3% on an organic basis in the first quarter, including double-digit growth in both the U.S. and internationally.
ABT
Apr 17, 2024 | 07:33 EDT
ABT
Apr 17, 2024 | 07:32 EDT
FY24 consensus $4.59. Abbott narrowed its full-year 2024 organic sales growth guidance range, excluding COVID-19 testing-related sales, to 8.5%-10.0%, which represents an increase at the midpoint of the range. Prior view was FY24 organic sales growth, excluding COVID-19 testing-related sales, in the range of 8.0%-10.0%. FY24 revenue consensus $41.99B.
ABT
Apr 17, 2024 | 07:30 EDT
Reports Q1 revenue $10B, consensus $9.88B. "Our first-quarter results reflect a strong start to the year, and we are raising our full-year sales and EPS guidance," said Robert Ford, chairman and CEO, Abbott. "This was the fifth consecutive quarter that we delivered double-digit organic sales growth in our underlying base business, which included particularly strong results in Medical Devices and Established Pharmaceuticals."
